US IN

(888) 440-0954

Press

Authored article by Dr Amit Chaudhuri on `Rational use of biomarkers in oncology clinical trials A paradigm shift towards precision medicine;

Biomarkers are biological indicators of early disease detection (diagnostic), disease progression and outcome (prognostic), and response to therapy (predictive).

Michael A. Nemzek appointed as MedGenome Chief Commercial Officer

Mr. Nemzek has held executive senior leadership team positions in both public companies and a number of private companies that have become successful public companies by merger and acquisition.

MedGenome to present its tumor microenvironment analysis results at the AACR Cancer Immunotherapy Conference in New York

The remarkable success of checkpoint control inhibitors in treating a variety of different cancers has necessitated a deeper assessment of the tumor and its microenvironment at the genetic and phenotypic level. Data from recent clinical trials has unequivocally established that the tumor microenvironment significantly impacts the efficacy of immune-oncology drugs.

MedGenome partners with ZellNet Consulting to offer powerful genomics solutions in immune-oncology research

This arrangement seamlessly integrates MedGenome’s cancer immunotherapy genomics platform with ZellNet’s immune monitoring services. This partnership will facilitate present customers of ZellNet’s immune monitoring services to quickly expand their cancer immunotherapy research into the genomics space by leveraging the power of next-generation sequencing-based approaches of neo-antigen and neo-epitope prediction.

Considering genomic research?

We’re at your service

*
 
*
*